Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    beckley psytech
Previous Study | Return to List | Next Study

Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05032833
Recruitment Status : Recruiting
First Posted : September 2, 2021
Last Update Posted : December 8, 2021
Sponsor:
Information provided by (Responsible Party):
Beckley Psytech Limited

Brief Summary:
The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects

Condition or disease Intervention/treatment Phase
Pharmacokinetics in Healthy Adults Drug: 5-MeO-DMT Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects
Actual Study Start Date : September 22, 2021
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2022

Arm Intervention/treatment
Experimental: 5-MeO-DMT arm Drug: 5-MeO-DMT
A single dose of 5-MeO-DMT will be administered intranasally

Placebo Comparator: Placebo arm Other: Placebo
A single dose of placebo will be administered intranasally




Primary Outcome Measures :
  1. Percentage of subjects with treatment emergent AEs (TEAES) [ Time Frame: From screening through to the follow up visit, up to 65 days ]

Secondary Outcome Measures :
  1. Peak plasma concentration (Cmax) [ Time Frame: Day 1 (dosing day) and Day 2 ]
  2. Time to reach Cmax (tmax) [ Time Frame: Day 1 (dosing day) and Day 2 ]
  3. Area under the plasma concentration- time curve [ Time Frame: Day 1 (dosing day) and Day 2 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

* Medically healthy based on medical records and study specific assessments

Exclusion Criteria:

* Presence or history of severe adverse reaction to any drug or drug excipient


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05032833


Contacts
Layout table for location contacts
Contact: Research Assistant 0203 299 1851/1852 5-MeO-DMT@kcl.ac.uk

Locations
Layout table for location information
United Kingdom
King's College London Recruiting
London, United Kingdom
Contact: James Rucker, MRCPsych         
Sponsors and Collaborators
Beckley Psytech Limited
Layout table for additonal information
Responsible Party: Beckley Psytech Limited
ClinicalTrials.gov Identifier: NCT05032833    
Other Study ID Numbers: BPL-5MEO-101
First Posted: September 2, 2021    Key Record Dates
Last Update Posted: December 8, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No